On the public citation graph

Risk of Fatigue in Cancer Patients Treated with Anti Programmed Cell Death-1/Anti Programmed Cell Death Ligand-1 Agents: A Systematic Review and Meta-Analysis

https://doi.org/10.2217/imt-2018-0067
0 signed · 50 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2017.2411openalex-snapshot
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
inferredcites →https://doi.org/10.1002/ijc.28715openalex-snapshot
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials
inferredcites →https://doi.org/10.1002/sim.1761openalex-snapshot
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
inferredcites →https://doi.org/10.1016/0197-2456(95)00134-4openalex-snapshot
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
inferredcites →https://doi.org/10.1016/j.ijsu.2010.02.007openalex-snapshot
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
inferredcites →https://doi.org/10.1016/s0140-6736(15)01281-7openalex-snapshot
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)00561-4openalex-snapshot
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32455-2openalex-snapshot
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00083-2openalex-snapshot
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)00175-3openalex-snapshot
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30066-3openalex-snapshot
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30098-5openalex-snapshot
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30364-3openalex-snapshot
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30496-xopenalex-snapshot
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30498-3openalex-snapshot
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
inferredcites →https://doi.org/10.1016/s1470-2045(16)30624-6openalex-snapshot
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
inferredcites →https://doi.org/10.1016/s1470-2045(17)30007-4openalex-snapshot
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
inferredcites →https://doi.org/10.1016/s1470-2045(17)30065-7openalex-snapshot
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30104-3openalex-snapshot
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(17)30169-9openalex-snapshot
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30181-xopenalex-snapshot
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot
Pembrolizumab versus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1602252openalex-snapshot
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1613683openalex-snapshot
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1709937openalex-snapshot
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1712126openalex-snapshot
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdx008openalex-snapshot
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
inferredcites →https://doi.org/10.1136/bmj.315.7109.629openalex-snapshot
Bias in meta-analysis detected by a simple, graphical test
inferredcites →https://doi.org/10.1136/bmj.326.7382.219openalex-snapshot
Interaction revisited: the difference between two estimates
inferredcites →https://doi.org/10.1200/jco.2014.59.0703openalex-snapshot
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
inferredcites →https://doi.org/10.1200/jco.2015.62.3397openalex-snapshot
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
inferredcites →https://doi.org/10.1200/jco.2015.63.7421openalex-snapshot
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
inferredcites →https://doi.org/10.1200/jco.2015.64.8931openalex-snapshot
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
inferredcites →https://doi.org/10.1200/jco.2016.66.9929openalex-snapshot
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2016.67.9761openalex-snapshot
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
inferredcites →https://doi.org/10.1200/jco.2016.70.1524openalex-snapshot
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
inferredcites →https://doi.org/10.1200/jco.2016.72.1340openalex-snapshot
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
inferredcites →https://doi.org/10.1634/theoncologist.12-s1-22openalex-snapshot
Mechanisms of Cancer-Related Fatigue
inferredcites →https://doi.org/10.2307/2533446openalex-snapshot
Operating Characteristics of a Rank Correlation Test for Publication Bias

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4159562openalex-extracted
Treatment-Related Adverse Events of PD-1 or PD-L1 Inhibitors for Triple Negative Breast Cancer Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/978-3-030-78648-9_11openalex-snapshot
Management of Cancer-Related Fatigue
inferred← citeshttps://doi.org/10.1007/s00761-021-01042-2openalex-snapshot
Tumorassoziierte Fatigue bei Immuncheckpointinhibitoren
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.